Conferences AASLD 2016
Other Infections
AASLD 2016: Is Improved Treatment Reducing Liver Cancer Among People with Hepatitis B?
- Details
- Category: HBV Disease Progression
- Published on Wednesday, 15 February 2017 00:00
- Written by Liz Highleyman
The incidence of hepatocellular carcinoma (HCC) appears to be decreasing and mortality improving among chronic hepatitis B patients treated with suppressive antiviral therapy, according to studies presented at the recent 2016 AASLD Liver Meeting in Boston. However, liver cancer remains a major indication for liver transplants and has a negative effect on survival of people with hepatitis B.
AASLD 2016: Lonafarnib Lowers Hepatitis Delta Levels with Acceptable Side Effects
- Details
- Category: Experimental HBV Drugs
- Published on Monday, 23 January 2017 00:00
- Written by Liz Highleyman
The hepatitis delta virus (HDV) assembly inhibitor lonafarnib reduces HDV viral load and can be safely boosted with ritonavir to allow for higher and more effective doses with acceptable gastrointestinal side effects, according to study results presented at the recent AASLD Liver Meeting in Boston.
AASLD 2016: Real-World Studies Show 8 Weeks of Sofosbuvir/Ledipasvir Equals 12 Weeks for Many Patients
- Details
- Category: HCV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by Keith Alcorn
An 8-week course of treatment with sofosbuvir/ledipasvir (Harvoni) is just as effective as a 12-week course for people with hepatitis C virus (HCV) genotype 1 without cirrhosis, including those with HIV/HCV coinfection, and could significantly reduce the cost of treatment if it was prescribed more widely, according to several large real-life cohort studies presented the 2016 AASLD Liver Meeting last month in Boston.
AASLD 2016: Is DAA Treatment for Hepatitis C Reducing the Need for Liver Transplants?
- Details
- Category: HCV Disease Progression
- Published on Sunday, 22 January 2017 00:00
- Written by Liz Highleyman
Patients successfully treated for hepatitis are less likely to need liver transplants and less likely to die while on a transplant waiting list, according to studies presented at the recent AASLD Liver Meeting. A related analysis looked at the optimal timing of treatment for people awaiting transplants in order to avoid "MELD purgatory."
AASLD 2016: Generic Sofosbuvir Underperforms in Real World, May Be Due to Suboptimal Regimens
- Details
- Category: HCV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by Michael Carter
Generic sofosbuvir-based combinations for hepatitis C may not perform as well as branded sofosbuvir-containing regimens, according to a study conducted in Qatar and presented at the recent 2016 AASLD Liver Meeting. People treated with generics were less likely to be cured and more likely to experience adverse events compared to people who received branded drugs. But the investigators speculate that the generics may have underperformed because many people treated were with suboptimal regimens, and believe this deserves further research.
AASLD 2016: Curing Hepatitis C Reduces Liver-Related Complications and Death
- Details
- Category: HCV Disease Progression
- Published on Wednesday, 18 January 2017 00:00
- Written by Liz Highleyman
People with hepatitis C who achieve sustained virological response to treatment had lower liver-related morbidity and mortality rates compared to patients who were not successfully treated, according to research presented at the recent AASLD Liver Meeting.
AASLD 2016: Glecaprevir/ Pibrentasvir Effective for Hepatitis C Patients with Severe Kidney Disease
- Details
- Category: HCV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by Liz Highleyman
A 2-drug pangenotypic regimen combining AbbVie's glecaprevir and pibrentasvir demonstrated a high sustained response rate for chronic hepatitis C patients with severe kidney impairment, according to results from the EXPEDITION-4 study presented at the 2016 AASLD Liver Meeting last month in Boston.
AASLD 2016: Liver Cirrhosis and Decompensation on the Rise Among People with Hepatitis C
- Details
- Category: HCV Disease Progression
- Published on Tuesday, 17 January 2017 00:00
- Written by Liz Highleyman
Complications of advanced liver disease including cirrhosis and hepatic decompensation have risen over the past decade among people with chronic hepatitis C, according to study findings presented at the AASLD Liver Meeting in November. However, in recent years the increase has slowed, especially among those at highest risk -- black patients and people age 60 and over.
AASLD 2016: Curing Hepatitis C May Help Reduce Kidney Disease Progression
- Details
- Category: HCV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by Liz Highleyman
People who achieved sustained virological response to interferon-based hepatitis C treatment experienced significantly less decline in kidney function, especially if they had liver cirrhosis, according to study findings presented at the 2016 AASLD Liver Meeting last month in Boston.
More Articles...
- AASLD 2016: Nivolumab Shows Good Safety and Promising Response Rates in Liver Cancer Study
- AASLD 2016: GS-4774 Therapeutic Vaccine Shows Little Efficacy in People with Hepatitis B
- AASLD 2016: 6 Weeks of Sofosbuvir/Ledipasvir Cures Genotype 1 Acute Hepatitis C
- AASLD 2016: Non-Adherence Is Most Important Risk Factor for Sofosbuvir/Ledipasvir Failure
- AASLD 2016: Portal Hypertension Less Likely to Improve After HCV Treatment When Fibrosis Is Severe
- AASLD 2016: Hepatitis C Virus Infections Rising Among HIV+ Gay Men in San Diego
- AASLD 2016: Nucleic Acid Polymers Reduce HBsAg Levels and Improve Control of Hepatitis B Virus
- AASLD 2016: Birth Cohort Screening and Linkage to Hepatitis C Care Still Weak in U.S.
- AASLD 2016: Sofosbuvir/ Ledipasvir Effective for HIV/HCV Coinfected People in Real-World Cohorts
- AASLD 2016: Primary Care Providers Can Effectively Treat Patients with Hepatitis C
- AASLD 2016: HIV/HCV Coinfected People See Good Cure Rates in Real-World Practice in Madrid
- Coverage of the 2016 AASLD Liver Meeting
- AASLD 2016: U.S. Veterans Health System and Australia Show Potential for Rapid Hepatitis C Elimination
- AASLD 2016: Grazoprevir Triple Regimen Demonstrates High Cure Rates, Even for Hard-to-Treat Patients
- AASLD 2016: 8-Week Triple Combo Cures Most Patients with Genotype 1-6 Hepatitis C
- AASLD 2016: AbbVie Pangenotypic Combination Cures 98% or More Across HCV Genotypes
- AASLD 2016: AbbVie Pangenotypic Combination Cures Hard-to-Treat People with HCV Genotype 3
- AASLD 2016: Tenofovir Alafenamide Approved for Hepatitis B, Works Well with Less Effect on Bones
- AASLD 2016: When You Eat May Contribute to Fatty Liver Disease as Much as What You Eat
- AASLD 2016: Grazoprevir/ Elbasvir + Sofosbuvir Highly Effective for Hard-to-Treat Genotype 3 HCV Patients
- AASLD 2016: Real-World Responses to HCV Treatment Among U.S. Veterans Match Best Clinical Trial Results
- AASLD 2016: Liver Cancer Risk Reduced After Hepatitis C Treatment, But Vigilance Needed
Web Design and Development by